Reactive arthritis after COVID-19: a case-based review.
Reads0
Chats0
TLDR
In this article, a 53-year-old female patient with acute monoarthritis after SARS-CoV-2 infection, who responded adequately to 150mg/day diclofenac treatment, and the available case reports are comprehensively reviewed.Abstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 19 (COVID-19) pandemic, which is deeply affecting the whole world. In this new case for the scientific world, scientists are investigating the etiopathogenesis of viral infection-induced damage and have started to focus on the short and long-term immune system effects and alterations after SARS-CoV-2 infection. The case is here reported of a 53-year-old female patient with acute monoarthritis after SARS-CoV-2 infection, who responded adequately to 150 mg/day diclofenac treatment, and the available case reports are comprehensively reviewed. With the focus on arthritis after SARS-CoV2 infection, which emerges as a new pathological condition associated with COVID-19, it was aimed to examine the possible immunological mechanisms of post-COVID-19 arthritis based on the current data on SARS-CoV-2 and the known pathogenetic background of viral arthritis.read more
Citations
More filters
Journal ArticleDOI
COVID-19 in Joint Ageing and Osteoarthritis: Current Status and Perspectives
TL;DR: It is hypothesize that SARS-CoV-2 contributes to age-related perturbations in endothelial and adipose tissue, which are known to characterize the early aging process, which would explain the long-lasting symptoms of Sars-Cov-2 as the result of an accelerated aging process.
Journal ArticleDOI
Reactive arthritis before and after the onset of the COVID-19 pandemic
TL;DR: This article proposed a wider definition of reactive arthritis (ReA) that considers any arthritis that occurs after a mucosal surface infection as ReA, which is a type of spondyloarthritis.
Journal ArticleDOI
Concurrent myopathy and inflammatory cardiac disease in COVID-19 patients: a case series and literature review
TL;DR: In this paper , the authors describe the incidence and characteristics of patients with the co-occurrence of COVID-19 myopathy and inflammatory cardiac disease in a large tertiary center.
Journal ArticleDOI
Musculoskeletal Manifestations of COVID-19: Currently Described Clinical Symptoms and Multimodality Imaging Findings
TL;DR: Imaging findings for various COVID-19–related MSK pathologic conditions across a variety of modalities are being recognized, which can be helpful for diagnosis, treatment guidance, and follow-up.
Journal ArticleDOI
New-onset Polymyalgia Rheumatica Following the Administration of the Pfizer-BioNTech COVID-19 Vaccine
TL;DR: The case of an 80-year-old Japanese woman with bilateral pain in the shoulders and hips lasting for a month since 2 days after the second dose of the BNT162b2 COVID-19 vaccine was reported in this article .
References
More filters
Journal ArticleDOI
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.
Jérôme Hadjadj,Nader Yatim,Laura Barnabei,Aurélien Corneau,Jeremy Boussier,Nikaïa Smith,Hélène Péré,Bruno Charbit,Vincent Bondet,Camille Chenevier-Gobeaux,Paul Breillat,Nicolas Carlier,Rémy Gauzit,Caroline Morbieu,Frédéric Pène,Nathalie Marin,Nicolas Roche,Tali Anne Szwebel,Sarah H. Merkling,Jean-Marc Treluyer,David Veyer,Luc Mouthon,Catherine Blanc,Pierre-Louis Tharaux,Flore Rozenberg,Alain Fischer,Alain Fischer,Alain Fischer,Darragh Duffy,Frédéric Rieux-Laucat,Solen Kernéis,Solen Kernéis,Benjamin Terrier +32 more
TL;DR: The results of this trio of studies suggest that the location, timing, and duration of IFN exposure are critical parameters underlying the success or failure of therapeutics for viral respiratory infections.
Journal ArticleDOI
Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.
TL;DR: Early recognition and appropriate treatment of immunologic complications will decrease the morbidity and mortality in COVID-19 infection, which requires the collaboration of infectious disease, lung, and intensive care unit specialists with other experts such as immunologists, rheumatologists, and hematologists.
Journal ArticleDOI
Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors
TL;DR: The aim of this review is to analyze the main steps in writing a narrative biomedical review and to consider points that may increase the chances of success.
Journal Article
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Piercarlo Sarzi-Puttini,Valeria Giorgi,Silvia Sirotti,Daniela Marotto,Sandro Ardizzone,Giuliano Rizzardini,Spinello Antinori,Massimo Galli +7 more
TL;DR: A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern.
Journal ArticleDOI
Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
TL;DR: Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leuc Openia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.